Vivani Medical, Inc.VANIEarnings & Financial Report
Nasdaq · Health Care · Electromedical & Electrotherapeutic Apparatus
Vivani Medical, Inc. is a clinical-stage biopharmaceutical firm specializing in miniaturized long-acting implantable drug delivery systems. Its core pipeline covers treatments for chronic conditions including diabetes and ophthalmic diseases, serving patients and healthcare partners across North America and select global markets.
VANI Q2 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-7.5M
Net Profit
$-7.1M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.12
Vivani Medical, Inc. Q2 FY2025 Financial Summary
Vivani Medical, Inc. reported revenue of $0 for Q2 FY2025, with a net profit of $-7.1M (down 33.4% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-7.1M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q2 FY2025 |
Vivani Medical, Inc. Quarterly Revenue & Net Profit History
Vivani Medical, Inc. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $0 | — | $-7.1M | N/A |
| Q1 FY2025 | $0 | — | $-6.3M | N/A |
| Q3 FY2024 | $0 | — | $-6.0M | N/A |
Income Statement
| Q3 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A |
Balance Sheet
| Q3 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|
| Assets | $42.9M | $35.5M | $28.9M |
| Liabilities | $24.6M | $23.8M | $24.0M |
| Equity | $18.3M | $11.6M | $4.9M |
Cash Flow
| Q3 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|
| Operating CF | $-5.7M | $-5.2M | $-6.1M |